Table 4.
Immunological outcomes after 4th dose of vaccination.
| Author | Median (IQR) delay between 3rd and 4th dose, days | Median (IQR) antibody IgG titer before the 4rd dose, BAU/mL | Median (IQR) antibody IgG titer after the 4th dose, BAU/mL | Ratio of the median antibody titer after/before the 4th dose | Median (IQR) timing of antibody IgG titer exam after the 4th dose, days |
|---|---|---|---|---|---|
| Caillard | 68 (61–74.7) | 16.4 (5.9–62.3) | 145 (27.6–243) | 8.8 | 29 (26–34) |
| Karaba | 93 (28–134) | 42.3 (4.9–134.2) | 228.9 (115.4–655.8) | 5.4 | 29 (17–38) |
| Kamar | 65 (9)* | 4 (1–9)**α | 9.5 (1.7–658)**β | 2.4 | 28 |
| Teles | NR | < 0.4–>2,500 γ | 1,750 (26–2,500) γ | – | 32 (28–34) |
| Mitchell | NR | 207 (11.6–1,500) γ | 2,132.5 (96.9–>2,500) γ | 10.3 | 14–28** |
| Osmanodja | 64 (55–84) | 42% δ | 74.2% δ | – | NR |
| Aikawa | 90 | 29.5 (23.3–37.4) ε | 215.8 (180.5–257.9) ε | 7.3 | 30 |
| Mrak | 84 | 0.4 (0.4–8.1) | 12.4 (0.4–197.3) | 31 | 30 |
| Ntanasis–Stathopoulos | 180 (150–210)** | 80 ± 3.5% ζ | 96.1 ± 3.7% ζ | – | 30 |
| Perrier | 201 (173–221) | η no = 174 (32.3%); weak = 103 (19.1%); strong = 261 (48.5%) | θ no = 56 (23.8%); weak = 26 (11.1%); strong = 153 (65.1%) | – | 31.5** |
| Assawasaksakul | 22 | 88 (49–155) | 644 (398–1,041) | 7 | 15 |
| Gössi | NR | < 12 (< 12–>400)**ε | 30.4 (< 12–400)**ε | – | 48–59** |
| Harberts | 126.0(93.0–148.0) | 134.6 ε | 1,196.0 ε | 9 | NR |
| Benjamini | 175 (174–175) | 4.3 (0.1–117.65) | 41.3 (0.4–1,185) | 10 | 14 |
| Midtvedt | 18.0 (9.7–18.3) weeks | 4.6 (2.5–32) | 1,553 (356–3,703) in 79 patients with >200 BAU/ ml 53 (12–407) in 96 patients sero–negative before dose 4 | – | 3–4 weeks |
| Peled | 173.4 ± 4.2* | 12.5 ε | 96.9 ε | 7.8 | 16.1 ± 4* |
| Thomson | 92–130** | 3,791 (1,142–5,680) in patients with history of SARS-CoV-2 infection 295 (9.1–1,611) in patients without previous SARS-CoV-2 infection |
3,993 (835–5,680) in patients with history of SARS-CoV-2 infection 437 (26–2,211) in patients without previous SARS-CoV-2 infection | – | 23–66** |
| Busà | 168.3 (116–246)** | 330.2 (59.02–1,001) | 1,020 (366.6–5,486) | 65.33 (26–127**) | |
| Brandstetter | 26 (26–27) | NR | 44.7 (17.9–111.6) | 26 (26–27) | |
| Hod | 175 (164–176) | 345 (124–956) 699 (244–2,008) η, |
2,118 (761–5,900) 2,489 (1,098–5,640) η | 29 (25–33) | |
| Bjorlykke | 84 | 5,087 (1,250–9,081) | 6,192 (2,878–11,243) | 2–4 weeks | |
| Lamacchia | 119 ± 2* | NR | NR | 7, 30, 60 days | |
| Affeldt | NR | 134.4 | NR | NR | |
| Davidov | 175 (164–176) | 345 (124–955) | 2,118 (761–5,900) | 29 (25–33) |
Continuous data are reported as median (IQR range).
BAU, basal antibody units; AU, antibody units; ELU, Elisa laboratory units.
*
mean (standard deviation);
**
median (range);
***
range.
αdata referring to 5 patients seropositive before the 4th dose.
βdata referring to 31 patients seronegative before the 4th dose.
γreported in U/mL.
δserological response rate.
εreported in AU/mL.
ζmedian neutrilizing antibodies levels.
ηdata referring to different groups according to the sierological response before the 4th vaccine dose.
θ235 patients had serological tests after the fourth dose.
NR, not reported.